Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Journal: Cancer Research

Published: 2020-11-15

DOI: 10.1158/0008-5472.can-19-2568

Affiliations: 3

Authors: 16

Go to article
Institutions Share
Taiho Pharmaceutical Co., Ltd., Japan 0.94
Osaka City University (OCU), Japan 0.06

Return